Data gathered: November 27
Alternative Data for Kintara Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 86 | Sign up | Sign up | Sign up |
| Webpage traffic | 6,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 8 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 16,106 | Sign up | Sign up | Sign up |
| Twitter Followers | 783 | Sign up | Sign up | Sign up |
| Twitter Mentions | 48 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 8 | Sign up | Sign up | Sign up |
About Kintara Therapeutics
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients.
| Price | $7.54 |
| Target Price | Sign up |
| Volume | 3,550,000 |
| Market Cap | $12M |
| Year Range | $0.22 - $11.44 |
| Dividend Yield | 0% |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
 |
Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024October 16 - Yahoo |
|
Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA BiosciencesOctober 16 - Yahoo |
 |
Kintara Therapeutics Stock to Reverse Split on Friday, October 18th (NASDAQ:KTRA)October 15 - ETF Daily News |
Kintara Therapeutics Announces Stock Split Amid MergerOctober 15 - TipRanks |
|
|
Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024October 15 - Yahoo |
Kintara Therapeutics Updates on Merger and CVR IssuanceOctober 14 - TipRanks |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '24 | 0 | 1.5M | -1.5M | -2M | -2.1M | -0.045 |
| Q4 '23 | 0 | 910,000 | -910,000 | -1M | -1M | -0.236 |
| Q3 '23 | 0 | 1.1M | -1.1M | -3M | -2.9M | -1.830 |
| Q2 '23 | 0 | 4.5M | -4.5M | -3.3M | -3.3M | -1.950 |
| Q1 '23 | 0 | 1.3M | -1.3M | -3.3M | -3.3M | -1.940 |
Insider Transactions View All
| Hoffman Robert E. filed to buy 55,000 shares at $0.5. February 17 '22 |
Similar companies
Read more about Kintara Therapeutics (KTRA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Kintara Therapeutics?
The Market Cap of Kintara Therapeutics is $12M.
What is the current stock price of Kintara Therapeutics?
Currently, the price of one share of Kintara Therapeutics stock is $7.54.
How can I analyze the KTRA stock price chart for investment decisions?
The KTRA stock price chart above provides a comprehensive visual representation of Kintara Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Kintara Therapeutics shares. Our platform offers an up-to-date KTRA stock price chart, along with technical data analysis and alternative data insights.
Does KTRA offer dividends to its shareholders?
As of our latest update, Kintara Therapeutics (KTRA) does not offer dividends to its shareholders. Investors interested in Kintara Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Kintara Therapeutics?
Some of the similar stocks of Kintara Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.